Have a feature idea you'd love to see implemented?
Let us know!
GOSS Gossamer Bio Inc
Price (delayed)
$0.6646
Market cap
$150.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$324.02M
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an
Highlights
GOSS's EPS has soared by 85% year-on-year and by 21% since the previous quarter
Gossamer Bio's net income has soared by 62% YoY and by 11% from the previous quarter
The debt has declined by 5% year-on-year but it rose by 2.4% since the previous quarter
GOSS's equity is down by 48% YoY and by 34% QoQ
The quick ratio is down by 18% since the previous quarter and by 16% year-on-year
Key stats
What are the main financial stats of GOSS
Market
Valuations
Earnings
Shares outstanding
226.6M
Market cap
$150.6M
Enterprise value
$324.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.78
Price to sales (P/S)
1.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.08
Revenue
$105.32M
EBIT
-$56.33M
EBITDA
-$52.24M
Free cash flow
-$1.41M
Per share
Balance sheet
Liquidity
EPS
-$0.26
Free cash flow per share
-$0.01
Book value per share
$0.24
Revenue per share
$0.47
TBVPS
$1.55
Total assets
$350.88M
Total liabilities
$296.74M
Debt
$201.88M
Equity
$54.14M
Working capital
$293.18M
Debt to equity
3.73
Current ratio
6.74
Quick ratio
6.53
Net debt/EBITDA
-3.32
Margins
Efficiency
Dividend
EBITDA margin
-49.6%
Gross margin
100%
Net margin
-68%
Operating margin
-69.1%
Return on assets
-22.1%
Return on equity
-127.3%
Return on invested capital
-12.9%
Return on capital employed
-18.8%
Return on sales
-53.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GOSS stock price
How has the Gossamer Bio stock price performed over time
Intraday
-4.58%
1 week
-13.69%
1 month
-27.84%
1 year
-12.5%
YTD
-27.17%
QTD
-32.62%
Financial performance
How have Gossamer Bio's revenue and profit performed over time
Revenue
$105.32M
Gross profit
$105.32M
Operating income
-$72.82M
Net income
-$71.65M
Gross margin
100%
Net margin
-68%
Gossamer Bio's net income has soared by 62% YoY and by 11% from the previous quarter
Gossamer Bio's operating income has surged by 61% YoY and by 8% QoQ
The net margin rose by 19% since the previous quarter
The operating margin is up by 17% since the previous quarter
Growth
What is Gossamer Bio's growth rate over time
Valuation
What is Gossamer Bio stock price valuation
P/E
N/A
P/B
2.78
P/S
1.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.08
GOSS's EPS has soared by 85% year-on-year and by 21% since the previous quarter
The P/B is 57% less than the 5-year quarterly average of 6.5 and 44% less than the last 4 quarters average of 5.0
GOSS's equity is down by 48% YoY and by 34% QoQ
GOSS's revenue is up by 10% QoQ
Efficiency
How efficient is Gossamer Bio business performance
The company's return on equity has surged by 96% YoY but it fell by 9% QoQ
Gossamer Bio's ROIC has soared by 74% YoY and by 14% from the previous quarter
GOSS's ROA has soared by 70% year-on-year and by 12% since the previous quarter
GOSS's ROS is up by 20% since the previous quarter
Dividends
What is GOSS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GOSS.
Financial health
How did Gossamer Bio financials performed over time
GOSS's total assets is 18% higher than its total liabilities
The total liabilities is up by 22% year-on-year
The current ratio has contracted by 18% from the previous quarter and by 16% YoY
The company's debt to equity has surged by 84% YoY and by 54% QoQ
GOSS's equity is down by 48% YoY and by 34% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.